Amyotrophic Lateral Sclerosis
CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
Published in Medical Letter on the CDC and FDA, July 15th, 2007
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, reported safety and tolerability results from its previously announced double-blind, placebo-controlled, rising multiple dose clinical trial in healthy volunteers with its drug candidate arimoclomol. CytRx believes that the results of this trial support the use of arimoclomol in future clinical trials, including its ALS Phase IIb clinical trial, at doses up to six-fold higher than that used in its previous Phase IIa clinical trials for ALS.
CytRx plans to begin its Phase IIb clinical trial in the second half of this year, subject to U.S....
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Anemia
Community Oncology explores pitched debate over anemia-fighting drugs - Epidemiology
Adding folic acid to bread could help in the fight against depression - Malaria
FDA Clears for Marketing First Quick Test for Malaria - Regulatory Actions
University Hospitals receives full accreditation from human research protection programs - Antibiotics
Wockhardt to launch Cefprozil, in the US, Eight FDA approval in 4 months - Asthma
Critical Therapeutics and Dey, L.P. Complete Definitive Co-Promotion Agreement for Perforomist Inhalation Solution - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
